Peripheral B lymphocyte β1,3‐galactosyltransferase and chaperone expression in immunoglobulin A nephropathy

. Purpose.  Aberrant O‐glycosylation of serum IgA1 is presumed to be one of the main pathogenesis of immunoglobulin A nephropathy (IgAN). β1,3‐galactosyltransferase (β1,3GT), whose activity requires coexistence of a specific chaperone, is the main enzyme which participate in the glycosylation proces...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of internal medicine 2005-11, Vol.258 (5), p.467-477
Hauptverfasser: QIN, W., ZHOU, Q., YANG, L.‐C., LI, Z., SU, B.‐H., LUO, H., FAN, J.‐M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:. Purpose.  Aberrant O‐glycosylation of serum IgA1 is presumed to be one of the main pathogenesis of immunoglobulin A nephropathy (IgAN). β1,3‐galactosyltransferase (β1,3GT), whose activity requires coexistence of a specific chaperone, is the main enzyme which participate in the glycosylation process. The current study was carried out to elucidate the expression level of β1,3GT (C1GALT1) and its chaperone (Cosmc) in IgAN, and their relationships with clinical features as well as IgA glycosylation level. Design, setting and subjects.  Forty‐one patients with IgAN, 21 patients with non‐IgAN glomerulonephritis and 26 normal controls were included in the present study. Peripheral B lymphocytes were isolated, and then expression level of C1GALT1 and Cosmc were quantitatively measured by real‐time reverse transcriptase polymerase chain reaction (RT‐PCR). Serum IgA level and glycosylation level were determined by enzyme‐linked immunosorbent assay (ELISA) and VV lectin‐binding method. Correlation analysis was performed between C1GALT1/Cosmc expression levels and clinical manifestations (severe proteinuria, renal dysfunction, gross haematuria). Results.  B‐lymphocyte Cosmc gene expression level was significantly lower in IgAN patients than that of normal control and non‐IgAN patients (P 
ISSN:0954-6820
1365-2796
DOI:10.1111/j.1365-2796.2005.01558.x